Fractyl Health, Inc. (NASDAQ:GUTS) CEO Harith Rajagopalan Sells 96,517 Shares

Fractyl Health, Inc. (NASDAQ:GUTS) CEO Harith Rajagopalan sold 96,517 shares of the firm’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $2.47, for a total value of $238,396.99. Following the completion of the sale, the chief executive officer now directly owns 491,329 shares of the company’s stock, valued at approximately $1,213,582.63. This represents a 16.42 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

Fractyl Health Price Performance

Shares of Fractyl Health stock opened at $2.09 on Friday. Fractyl Health, Inc. has a 52 week low of $1.74 and a 52 week high of $14.50. The company has a quick ratio of 7.46, a current ratio of 5.58 and a debt-to-equity ratio of 0.60. The company has a 50 day moving average price of $2.61 and a 200 day moving average price of $4.04.

Fractyl Health (NASDAQ:GUTS) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.48) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.02. The company had revenue of $0.01 million for the quarter. As a group, equities research analysts predict that Fractyl Health, Inc. will post -1.61 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Fractyl Health

A number of large investors have recently bought and sold shares of the company. M28 Capital Management LP acquired a new stake in shares of Fractyl Health in the first quarter worth $13,735,000. American International Group Inc. acquired a new position in shares of Fractyl Health in the 1st quarter valued at about $9,911,000. Massachusetts Financial Services Co. MA boosted its stake in shares of Fractyl Health by 4.9% in the third quarter. Massachusetts Financial Services Co. MA now owns 1,045,672 shares of the company’s stock worth $2,646,000 after buying an additional 49,289 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Fractyl Health by 56.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 80,664 shares of the company’s stock worth $204,000 after acquiring an additional 29,262 shares during the period. Finally, Beta Wealth Group Inc. acquired a new position in Fractyl Health in the third quarter valued at approximately $44,000.

Fractyl Health Company Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.